Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3235 | RS blend Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
There is an evidence gap in relation to the incidence, impact and severity of COVID-19 in newborn babies. International data are very limited, we have no robust estimates of incidence and no UK-based data with which to inform policy, clinical care, service delivery or advice to pregnant women. The research aims are to investigate the three mains ways in which COVID-19 might affect newborns and babies that need neonatal care: 1. Newborn babies might catch COVID-19 before, during or soon after birth and this may lead to problems with breathing or feeding that need support in hospital. 2. COVID-19 could affect babies that are already on neonatal units with other medical conditions (like being very premature) that place them at greater risk of severe COVID-19. 3. COVID-19 might affect that way that pregnant women are looked after in pregnancy, labour or bith which could lead to problems for some babies, even if they do not themselves become infected with COVID-19.
Description: Number of neonatal participants with COVID-19 divided by the total number of live births in the population
Measure: Incidence of neonatal COVID-19 Time: April 2020 to March 2021Description: Number of neonatal participants with COVID-19 following vertically transmission of the Coronavirus divided by the total number of live births in the population
Measure: Incidence of vertically transmitted COVID-19 Time: April 2020 to March 2021Description: Questionnaire data
Measure: Presentation and natural history of neonatal COVID-19 Time: April 2020 to March 2021Description: Questionnaire data
Measure: Presentation of neonates with COVID-19 positive mothers Time: April 2020 to March 2021Description: Proportion of neonate participants who died and the proportion who were discharged home alive.
Measure: Outcomes for neonates with COVID-19 Time: April 2020 to March 2021Description: Questionnaire data
Measure: Clinical treatment of neonatal COVID-19 Time: April 2020 to March 2021Description: Questionnaire data
Measure: Neonatal secondary impacts of maternal COVID-19 Time: April 2020 to March 2021Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports